Abstract：
Development of periungual pyogenic granulomas (pPGs) has been associated with several systemic treatments, including retinoids, taxanes, epidermal growth factor receptor inhibitors, and vascular endothelial growth factor inhibitors. We present the case of an 8-year-old girl with a personal history of acute myelomonocytic leukemia treated with a haploidentical hematopoietic stem cell transplant who developed pPGs 2 months after starting ravulizumab. Ravulizumab is a monoclonal antibody directed against C5 protein. No previous reports of pPGs development have been described with ravulizumab.
摘要：
甲周化脓性肉芽肿（pPG）的发展与几种全身治疗有关，包括类维生素A,紫杉烷,表皮生长因子受体抑制剂，血管内皮生长因子抑制剂.我们介绍了一个8岁女孩的病例，该女孩有急性骨髓单核细胞白血病的个人病史，接受了单倍相合造血干细胞移植，在开始ravulizumab治疗2个月后出现了pPG。Ravulizumab是针对C5蛋白的单克隆抗体。以前没有关于ravulizumab开发pPG的报道。
